3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
14
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
28
Trastuzumab
16
Paclitaxel
14
Docetaxel
12
Cyclophosphamide
11
Capecitabine
11
Nivolumab
9
fludarabine
7
Carboplatin
7
Oxaliplatin
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
Specimen Handling
5
Leucovorin
5
Irinotecan
5
Injections
5
Gemcitabine
5
Fluorouracil
5
Bevacizumab
5
atezolizumab
4
aldesleukin
4
Taxes
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
zanidatamab
3
veliparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
AZD9833
×
Breast
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled